PMID- 30778554
OWN - NLM
STAT- Publisher
LR  - 20190219
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
DP  - 2019 Feb 19
TI  - A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the
      prevention of neonatal group B streptococcal infections by maternal immunization.
LID - jiz062 [pii]
LID - 10.1093/infdis/jiz062 [doi]
AB  - BACKGROUND: Group B streptococcus (GBS) causes serious diseases in newborn
      infants, often resulting in lifelong neurologic impairments or death.
      Prophylactic vaccination of pregnant women prior to delivery could provide
      comprehensive protection, as early and late onset disease and maternal
      complications potentially could be addressed. METHODS: Capsular polysaccharide
      conjugate vaccine GBS6 was designed using Whole Genome Sequencing surveillance
      data of recent, global GBS isolates responsible for invasive neonatal GBS
      disease. Capsular polysaccharides were isolated, oxidized using sodium periodate 
      and conjugated to CRM197 by reductive amination in dimethyl sulfoxide. Immune
      responses in mice and rhesus macaques were measured in a multiplex Luminex IgG
      assay and opsonophagocytic activity assays. RESULTS: The optimized conjugates
      were immunogenic, alone and in combination, in mice and rhesus macaques, inducing
      IgG antibodies that mediated opsonophagocytic killing. Active immunization of
      murine dams with GBS6 prior to mating resulted in serotype-specific protection of
      pups from a lethal challenge with group B streptococcus. Protection following
      passive administration of serotype-specific IgG monoclonal antibodies to dams
      demonstrated conclusively that anti-capsular polysaccharide IgG alone is
      sufficient for protection. CONCLUSIONS: The findings support the ongoing clinical
      evaluation of maternal GBS6 vaccination as a potential alternative prevention
      method of GBS disease in infants.
CI  - (c) The Author(s) 2019. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Buurman, Ed T
AU  - Buurman ET
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Timofeyeva, Yekaterina
AU  - Timofeyeva Y
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Gu, Jianxin
AU  - Gu J
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Kim, Jin-Hwan
AU  - Kim JH
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Kodali, Srinivas
AU  - Kodali S
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Liu, Yongdong
AU  - Liu Y
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Mininni, Terri
AU  - Mininni T
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Moghazeh, Soraya
AU  - Moghazeh S
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Pavliakova, Danka
AU  - Pavliakova D
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Singer, Christine
AU  - Singer C
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Singh, Suddham
AU  - Singh S
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Handke, Luke D
AU  - Handke LD
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Lotvin, Jason
AU  - Lotvin J
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Prasad, A Krishna
AU  - Prasad AK
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Scully, Ingrid L
AU  - Scully IL
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Donald, Robert G K
AU  - Donald RGK
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Jansen, Kathrin U
AU  - Jansen KU
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
FAU - Anderson, Annaliesa S
AU  - Anderson AS
AD  - Vaccine Research and Development, Pfizer Inc., Pearl River, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20190219
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
OTO - NOTNLM
OT  - Streptococcus agalactiae
OT  - CRM197
OT  - GBS6
OT  - capsular polysaccharide
OT  - conjugate
OT  - group B streptococcus
OT  - maternal vaccine
EDAT- 2019/02/20 06:00
MHDA- 2019/02/20 06:00
CRDT- 2019/02/20 06:00
PHST- 2018/10/10 00:00 [received]
PHST- 2019/02/20 06:00 [entrez]
PHST- 2019/02/20 06:00 [pubmed]
PHST- 2019/02/20 06:00 [medline]
AID - 5336091 [pii]
AID - 10.1093/infdis/jiz062 [doi]
PST - aheadofprint
SO  - J Infect Dis. 2019 Feb 19. pii: 5336091. doi: 10.1093/infdis/jiz062.